- Home
- NUVL vs LSCC Comparison
NUVL vs LSCC Comparison
Compare NUVL & LSCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- LSCC
- Stock Information
- Founded
- NUVL 2017
- LSCC 1983
- Country
- NUVL United States
- LSCC United States
- Employees
- NUVL N/A
- LSCC N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- LSCC Semiconductors
- Sector
- NUVL Health Care
- LSCC Technology
- Exchange
- NUVL Nasdaq
- LSCC Nasdaq
- Market Cap
- NUVL 5.8B
- LSCC 6.9B
- IPO Year
- NUVL 2021
- LSCC 1989
- Fundamental
- Price
- NUVL $77.76
- LSCC $48.99
- Analyst Decision
- NUVL Strong Buy
- LSCC Strong Buy
- Analyst Count
- NUVL 10
- LSCC 12
- Target Price
- NUVL $119.60
- LSCC $63.58
- AVG Volume (30 Days)
- NUVL 482.8K
- LSCC 1.9M
- Earning Date
- NUVL 08-11-2025
- LSCC 08-04-2025
- Dividend Yield
- NUVL N/A
- LSCC N/A
- EPS Growth
- NUVL N/A
- LSCC N/A
- EPS
- NUVL N/A
- LSCC 0.37
- Revenue
- NUVL N/A
- LSCC $488,736,000.00
- Revenue This Year
- NUVL N/A
- LSCC $3.41
- Revenue Next Year
- NUVL N/A
- LSCC $18.44
- P/E Ratio
- NUVL N/A
- LSCC $132.43
- Revenue Growth
- NUVL N/A
- LSCC N/A
- 52 Week Low
- NUVL $55.54
- LSCC $34.69
- 52 Week High
- NUVL $113.51
- LSCC $70.55
- Technical
- Relative Strength Index (RSI)
- NUVL 43.20
- LSCC 39.37
- Support Level
- NUVL $77.41
- LSCC $50.63
- Resistance Level
- NUVL $83.50
- LSCC $54.56
- Average True Range (ATR)
- NUVL 3.08
- LSCC 2.16
- MACD
- NUVL -0.75
- LSCC -0.49
- Stochastic Oscillator
- NUVL 14.84
- LSCC 29.92
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About LSCC Lattice Semiconductor Corporation
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.